Grassi G G
Infection. 1986;14 Suppl 4:S300-2. doi: 10.1007/BF01661299.
A multicenter trial on the efficacy and tolerability of ofloxacin in upper and lower respiratory tract infections and urinary tract infections was carried out on 1,436 patients (926 males and 510 females; mean age 55.9 +/- 18.4 years). Three dosage regimens were randomly applied: 200 mg, 300 mg and 400 mg ofloxacin b.i.d. by the oral route. The overall clinical outcome expressed as the ratio of the number of patients cured and improved to the number of patients treated was 279/324 (86%) in upper respiratory tract infections; 612/667 (91.8%) in lower respiratory tract infections and 418/445 (93.9%) in urinary tract infections. Out of 872 bacterial strains isolated in 802 patients, 742 (85.1%) were eradicated. Side effects not requiring interruption of therapy were observed in 65 patients (4.5%), while interruption was necessary in 23 patients (1.6%). The most frequent side effects were gastrointestinal disturbances. In conclusion ofloxacin showed a good clinical efficacy and tolerability in the treatment of respiratory and urinary tract infections.
对1436例患者（926例男性和510例女性；平均年龄55.9±18.4岁）进行了一项关于氧氟沙星治疗上、下呼吸道感染及尿路感染的疗效和耐受性的多中心试验。随机采用三种给药方案：口服氧氟沙星，200毫克、300毫克和400毫克，每日两次。以上呼吸道感染为例，以治愈和好转患者数与治疗患者数之比表示的总体临床疗效为279/324（86%）；下呼吸道感染为612/667（91.8%），尿路感染为418/445（93.9%）。在802例患者分离出的872株细菌中，742株（85.1%）被根除。65例患者（4.5%）出现了无需中断治疗的副作用，而23例患者（1.6%）则有必要中断治疗。最常见的副作用是胃肠道不适。总之，氧氟沙星在治疗呼吸道和尿路感染方面显示出良好的临床疗效和耐受性。
